Brind.
  1. Protagonist Therapeutics submitted an NDA for its icotrokinra treatment and presented rusfertide data at the ASCO meeting.

Protagonist Therapeutics belongs to the biomedical and genetics industry sector.

1 report, 1 independent Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Protagonist Therapeutics belongs to the biomedical and genetics industry sector.

Who's involved

What this event is mainly about
Protagonist Therapeutics (United States)

Keep exploring

Part of

Protagonist Therapeutics submitted an NDA for its icotrokinra treatment and presented rusfertide data at the ASCO meeting. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksProtagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss